Background
Methods
Objective
Echocardiography
STE analysis for deformation
Materials
Animals
Streptozotocin (STZ)-induced type 1-like diabetic rats
Cell cultures
Western blotting analysis
Small interfering RNA (siRNA) transfection assay
Reverse transcription polymerase chain reaction (RT–PCR)
Statistical analysis
Results
Telmisartan improved cardiac remodeling in diabetic patients
Normal control (n = 10) | Baseline (n = 15) | After telmisartan (n = 15) |
p value | |
---|---|---|---|---|
Age (years) | 52.2 ± 8.5 | 55.3 ± 8.8 | – | 0.25 |
Male (%) | 6 (60) | 11 (73.3) | – | 0.12 |
Body height (cm) | 165.8 ± 7.4 | 163.9 ± 8.7 | – | 0.72 |
Body weight (kg) | 68.6 ± 7.1 | 70.8 ± 10.6 | – | 0.81 |
Heart rate (beats/min) | 69.8 ± 7.6 | 73.5 ± 8.24 | 72.38 ± 11.74 | 0.64 |
Systolic blood pressure (mmHg) | 120.2 ± 12.9 | 129.6 ± 17.1 | 122.1 ± 14.4 | 0.06 |
Diastolic blood pressure (mmHg) | 83 ± 8.9 | 82.6 ± 7.7 | 85.2 ± 13.9 | 0.43 |
Preprandial serum glucose (mg/dL) | 92.7 ± 5.6 | 122 ± 15.8 | 105.3 ± 10.6 |
0.01
|
HbA1c (%) | 5.6 ± 0.9 | 7.8 ± 1.2 | 7.2 ± 0.8 |
0.02
|
Creatinine clearance rate (ml/min) | 108.7 ± 45.8 | 83.7 ± 24.5 | 95.8 ± 24.6 | 0.29 |
Triglyceride (mg/dL) | 122.6 ± 51.3 | 129 ± 6.2 | – | 0.59 |
Cholesterol (mg/dl) | 178.7 ± 28.8 | 178.6 ± 32.3 | – | 0.67 |
Normal control (n = 10) | Baseline (n = 15) | After telmisartan (n = 15) |
p value | |
---|---|---|---|---|
LVMI (g/m2) | 83.3 ± 29.1 | 84.5 ± 29.8 | 85.1 ± 30.2 | 0.63 |
LVIDd (cm) | 4.2 ± 0.8 | 4.1 ± 0.7 | 4.1 ± 1.4 | 0.52 |
LVEF (%) | 70.5 ± 6.4 | 68.1 ± 4.5 | 69.3 ± 15.7 | 0.38 |
E (cm/s) | 76.5 ± 18.3 | 79.5 ± 12.3 | 82.7 ± 18.3 | 0.72 |
E/A | 1.0 ± 0.3 | 1.0 ± 0.2 | 0.9 ± 0.6 | 0.06 |
e′ (cm/s) | 10.3 ± 2.8 | 8.2 ± 1.8 | 9.3 ± 2.7 |
0.01
|
IVRT (ms) | 94.7 ± 23 | 96.6 ± 13.1 | 90.7 ± 21.5 | 0.06 |
DT (ms) | 200.5 ± 58.6 | 184.1 ± 52.2 | 198.4 ± 43.7 | 0.93 |
MPI | 0.4 ± 0.2 | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.35 |
GLS (%) | −20.2 ± 6.7 | −16.4 ± 5.2 | −18.1 ± 6.2 |
0.03
|
GCS (%) | −22.2 ± 7.8 | −14.7 ± 8.6 | −20.8 ± 6.8 |
0.01
|